PATENT CLAIM ANALYSIS

Application Number: 16163605
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "019600"]

Abstract:
There is provided a method of treating acute myeloid leukemia (AML). The method includes the step of administering to a patient having AML with a FMS-like tyrosine kinase 3 (FLT3)-mutation a therapeutically effective amount of a CXCR4-antagonistic peptide.

Claim (Index 11):
The method of  claim 9 , wherein said Flt-3 inhibitor synergizes with said CXCR4-antagonistic peptide in inducing apoptosis of AML cells.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 97.0
- Lexical Diversity: 1.32353
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13360751', '14395842', '12520699', '11915428', '12520811']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7388725773709143
- 35 USC 102 Novelty (BERT): 0.5409029082785829
- Combined Prediction Score: 0.7190756104616812
- Mean Citation Score: 330.028458
- Max Citation Score: 359.19586
- Similarity Product: 229.74331303562164

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test